MarinaYKonoplevaMD

PubMed

• Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals.
  Jitesh D Kawedia, Caitlin R Rausch, Xiaoqian Liu, Wei Qiao, Courtney D Dinardo
  American Journal of Hematology. 2025-04-01
• BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism.
  Kapil Saxena, Shao-Hsi Hung, Esther Ryu, Shailbala Singh, Qi Zhang Tatarata
  Cell Death Discovery. 2025-03-26
• Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts.
  Nicholas J Short, Ibrahim Aldoss, Daniel J DeAngelo, Marina Konopleva, Jessica Leonard
  Blood Advances. 2025-03-25

Journal Articles

• CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
  L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
• An Inhibitor of Oxidative Phosphorylation Exploits Cancer Vulnerability  
  Marina Konopleva, Sergej Konoplev, Nature
• BCL-2 Inhibition in AML - an Unexpected Bonus?  
  Marina Konopleva, Anthony Letai, Blood
• PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in Cancer  
  Michael Andreeff, Marina Konopleva, Nature
• Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia  
  Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
• Join now to see all

Abstracts/Posters

• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) ...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Dr...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Pre...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
  Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Metabolism and Hematologic Malignancies 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Ta... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all